Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIXNASDAQ:GNLXNASDAQ:HURANASDAQ:INKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.38+2.1%$2.90$2.07▼$4.20$106.62M0.34103,883 shs76,947 shsGNLXGenelux$3.05+3.7%$2.69$1.60▼$5.89$110.94M-0.49189,399 shs39,235 shsHURATuHURA Biosciences$2.29+2.7%$3.31$1.80▼$7.93$97.41M0.23244,033 shs251,247 shsINKTMiNK Therapeutics$7.48-1.5%$7.39$4.56▼$13.79$30.25M0.1513,065 shs1,571 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences+2.11%-4.79%+35.20%+13.80%+42.62%GNLXGenelux+3.74%+4.45%+20.08%-0.97%+41.86%HURATuHURA Biosciences+2.69%-15.19%-22.11%-35.13%+228,999,900.00%INKTMiNK Therapeutics-1.52%+0.61%+2.54%-17.22%-16.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIXAnixa Biosciences3.3294 of 5 stars3.65.00.00.01.83.30.0GNLXGenelux0.7746 of 5 stars3.60.00.00.00.00.00.0HURATuHURA Biosciences1.5039 of 5 stars3.70.00.00.02.00.00.0INKTMiNK Therapeutics2.6344 of 5 stars3.55.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 3.25Buy$9.00166.27% UpsideGNLXGenelux 3.20Buy$17.75481.97% UpsideHURATuHURA Biosciences 3.40Buy$12.67453.13% UpsideINKTMiNK Therapeutics 3.00Buy$37.50401.67% UpsideCurrent Analyst Ratings BreakdownLatest INKT, GNLX, HURA, and ANIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025HURATuHURA BiosciencesBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/29/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/16/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.005/8/2025GNLXGeneluxBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.004/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/3/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.003/31/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K518.43N/AN/A$0.46 per share7.35GNLXGenelux$10K11,510.70N/AN/A$0.76 per share4.01HURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/AINKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$12.55M-$0.38N/A∞N/AN/A-68.17%-60.38%9/5/2025 (Estimated)GNLXGenelux-$29.87M-$0.88N/AN/AN/AN/A-93.04%-74.17%8/13/2025 (Estimated)HURATuHURA Biosciences-$21.68MN/A0.00∞N/AN/A291.69%122.09%N/AINKTMiNK Therapeutics-$9.51M-$2.52N/AN/AN/AN/AN/A-140.72%8/12/2025 (Estimated)Latest INKT, GNLX, HURA, and ANIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2025Q2 2025ANIXAnixa Biosciences-$0.10-$0.09+$0.01-$0.09N/AN/A5/15/2025Q1 2025HURATuHURA Biosciences-$0.13-$0.15-$0.02-$0.15N/AN/A5/15/2025Q1 2025INKTMiNK Therapeutics-$0.61-$0.70-$0.09-$0.70N/AN/A5/8/2025Q1 2025GNLXGenelux-$0.24-$0.21+$0.03-$0.21N/AN/A3/28/2025Q4 2024GNLXGenelux-$0.17-$0.26-$0.09-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A8.898.89GNLXGeneluxN/A4.674.67HURATuHURA BiosciencesN/A3.003.00INKTMiNK TherapeuticsN/A0.300.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%GNLXGenelux37.33%HURATuHURA Biosciences0.62%INKTMiNK Therapeutics2.87%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences25.30%GNLXGenelux9.30%HURATuHURA Biosciences0.20%INKTMiNK Therapeutics22.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences532.21 million24.06 millionOptionableGNLXGenelux1037.74 million34.23 millionNot OptionableHURATuHURA BiosciencesN/A43.68 million43.59 millionN/AINKTMiNK Therapeutics303.99 million3.09 millionNo DataINKT, GNLX, HURA, and ANIX HeadlinesRecent News About These CompaniesMiNK Therapeutics Announces Virtual Annual Shareholders MeetingJune 10, 2025 | globenewswire.comMiNK Therapeutics Receives NIAID Grant to Advance Allo-iNKT Cell Therapy for Graft-Versus-Host Disease TreatmentJune 4, 2025 | nasdaq.comMiNK Therapeutics ontvangt NIH-subsidie voor GvHD-therapieJune 2, 2025 | nl.investing.comMiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant PatientsJune 2, 2025 | globenewswire.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comQ1 2025 Mink Therapeutics Inc Earnings CallMay 16, 2025 | finance.yahoo.comMiNK Therapeutics Inc (INKT) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 16, 2025 | finance.yahoo.comMiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programsMay 15, 2025 | msn.comMiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comMiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic ProgressMay 15, 2025 | globenewswire.comA Look at MiNK Therapeutics's Upcoming Earnings ReportMay 14, 2025 | benzinga.comMiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial ReportMay 5, 2025 | globenewswire.comEarnings call transcript: Mink Therapeutics Q4 2024 reports reduced net lossMarch 20, 2025 | uk.investing.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | msn.comMiNK Therapeutics reports Q4 EPS (62c), consensus (50c)March 19, 2025 | markets.businessinsider.comQ4 2024 Mink Therapeutics Inc Earnings CallMarch 19, 2025 | finance.yahoo.comMink Therapeutics rapporteert lager nettoverlies in Q4 2024March 18, 2025 | nl.investing.comMiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call TranscriptMarch 18, 2025 | seekingalpha.comMiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business ProgressMarch 18, 2025 | globenewswire.comAre MiNK Therapeutics, Inc. (NASDAQ:INKT) Investors Paying Above The Intrinsic Value?March 5, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINKT, GNLX, HURA, and ANIX Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.38 +0.07 (+2.11%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$3.27 -0.11 (-3.25%) As of 06/26/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Genelux NASDAQ:GNLX$3.05 +0.11 (+3.74%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$3.04 -0.01 (-0.49%) As of 06/26/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.TuHURA Biosciences NASDAQ:HURA$2.29 +0.06 (+2.69%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.34 +0.04 (+1.97%) As of 06/26/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.MiNK Therapeutics NASDAQ:INKT$7.48 -0.12 (-1.52%) Closing price 06/26/2025 03:58 PM EasternExtended Trading$7.53 +0.05 (+0.72%) As of 06/26/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
